Navigation Links
BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
Date:1/8/2014

s approved for marketing as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium). Auxilium is partnered with Actelion Pharmaceuticals Ltd. for the marketing of XIAFLEX in Canada and Australia, and Swedish Orphan Biovitrium AB for the marketing of XIAPEX® (the EU tradename for CCH) in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome in a Phase 2b study and also for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas. For more information, please visit www.biospecifics.com.

Forward-Looking Statements
This release includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements." The forward-looking statements include statements concerning, among other things, the design and timing of future studies to access the efficacy and safety of CCH for the treatment of human lipoma or their likelihood of success; the potential of CCH for the treatment of human lipomas by comparison with surgery; whether Auxilium will exercise its opt-in rights for human lipoma following the completion of a new trial; and the development of CCH for other
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... YORK , 22 de mayo de ... DPRX ), una compañía farmacéutica de ... comercialización de Locilex® (pexiganan cream 0.8%), y ... una presentación de póster destacando el diseño ... 3 de la Compañía que evalúan Locilex®, ...
(Date:5/22/2015)... N.C. , May 22, 2015  Effective ... to pharmaceutical brand recognition and success. ... conducted a study to provide pharmaceutical and biotech ... investment (FTEs and budget) that are being channeled ... and biotech marketing managers can utilize this report ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2
... and Chicago To Launch,Collaborative Initiative, NEW YORK, ... speed,treatment and cures for pediatric brain tumors and ... the initial phase of a tissue,bank consortium designed ... and cures for these types of cancer, where ...
... Study to Evaluate Preventive Treatment of ... Life Threatening Vulnerable Plaques, ROTTERDAM, Netherlands and DOYLESTOWN, ... Professor Patrick W. Serruys,successfully placed a vProtect(TM) Luminal Shield ... 64-year-old man at Erasmus Medical,Center in Rotterdam. This case ...
Cached Medicine Technology:Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research 2Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research 3Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3
(Date:5/25/2015)... A recent report for Mass Live ... died as a direct result of an opiate overdose in ... rise in overdose deaths attributed to prescription opiate medications, and ... care about geography. This issue doesn’t care about race. This ... class.” As the state of Mass. reels from the effects ...
(Date:5/25/2015)... After the sensational buzz surrounding their ... wellness company Trivedi Master Wellness™ agrees to ... series titled, “Consciousness is Power.” Presently, the Live-Streaming event ... at the routinely allotted time from 10:00pm PST/1:00pm EST ... made available to the public and accessible on the ...
(Date:5/24/2015)... New York, NY (PRWEB) May 24, 2015 ... begins on Sunday, May 24th in San Diego at Petco ... tour throughout North America. On May 20th, they had ... Theatre. At their preview show in Los Angeles, this ... its entirety; they also played fan favorites such as "Jumping ...
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... 24, 2015 ... - The students were selected ... the fourth annual A Day of ... Geneva National in Lake Geneva. , ... High School,         Jonathan Alfonso,         Bridget Keefe, ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... study of sexual risk behaviors within long-term couples in ... much risk in their sexual behavior when they know ... as when they know their partner is already infected. ... antiretroviral therapy and in intensive counseling do engage in ...
... Boston University School of Medicine (BUSM) have discovered that ... have the propensity to become autoantigens. In a companion ... with dead cells and that the resulting DSautoantigen complexes ... in-vitro and in mouse models. These findings, which appear ...
... Slone Epidemiology Center, in collaboration with the Centers for ... Public Health, have reported widespread and increasing medication use ... in the American Journal of Obstetrics and Gynecology ... status, maternal age, race/ethnicity and state of residence. ...
... PA April 22, 2011 - Sanofi Pasteur, the ... NYSE: SNY), announced today that the U.S. Food and ... indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups ... Vaccine), to include a two-dose schedule for infants and ...
... (HealthDay News) -- While it may be true that beauty ... model helps reveal what,s behind peoples, ideas of facial attractiveness. ... "average" faces and those who fit the conventional notion of ... "femininity" in women. But psychologists Christopher P. Said of New ...
... American Society of Pediatric Otolaryngology (ASPO) will hold its ... 2011 Combined Otolaryngology Spring Meetings (COSM) - a joint ... During the ASPO meeting, hundreds of pieces of new ... will be presented focusing on children,s ear, nose, and ...
Cached Medicine News:Health News:Fighting HIV in South Africa should focus on couples, study finds 2Health News:Fighting HIV in South Africa should focus on couples, study finds 3Health News:Researchers identify novel pathophysiologic mechanism responsible for autoimmunity 2Health News:Researchers report widespread use of medications among pregnant women 2Health News:Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants 2Health News:What Makes a Face Appealing to the Opposite Sex? 2Health News:Scientific session and new research highlights from the American Society of Pediatric Otolaryngology Meeting 2
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits....
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: